Definium Therapeutics, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 8-K, Regulation FD disclosureSep 14 →InsidersNo open-market buys. 3 insiders sold $1.4M, all 6 sales on a 10b5-1 plan.→HoldersBlackRock 8.4%Avoro Capital 5.4%Driehaus 5.1%→Financing →PeersClosest companies: ATAI, ALT, TECX→
From the filings
Figures
- Net income
- −$353.8Mlast 12 months
- Operating cash flow
- −$144.8Mlast 12 months
- Cash and equivalents
- $655.3Mat the last balance sheet
- Total debt
- $36.5Mat the last balance sheet
- Shares outstanding
- 134.4M shareson issue